Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

Abstract: In a perimetry to be conducted, designating an inspection region through a region designator, a perimeter is configured to set a required time of the perimetry (upper limit time) through an upper limit condition setter and to determine total number or positions of stimulus presentation spots based upon the upper limit time. In such a configuration, an examinee knows the time to finish the inspection, and is able to highly keep his (her) concentration in comparison with a case where the required time is not known, thereby improving precision of the inspection.

Abstract: Provided is technology which can prevent the circumferential section of the end surface of a tip end opening from being damaged when an intraocular lens is extruded from an insertion apparatus, even when an insertion tube of the intraocular lens insertion apparatus has been further reduced in size.

Abstract: A waterproof wall 60 is provided to be interposed between an end face 31 of a base end section of a waterproof lens unit 20 and a mount face 13 of a camera body 10, thereby shutting off the front surface of the camera body 10 from a space in front of the front surface of the camera body 10 by the waterproof wall 60.

Abstract: A lens barrel detachably attached to a camera body includes a fixed tube section that has a base end installed at the camera body, and a top end, a first pitch screw section being formed on an inner peripheral surface of the top end; a movable tube section that is a tube member configured to hold a plurality of lens and has a second pitch screw section on the movable tube side formed at an outer peripheral surface, and is located so as to be movable inside the fixed tube section in such a state that the second pitch screw section is threadedly engaged with the first pitch screw section, the plurality of lens including two group of lenses, a first group and a second group, held within the movable tube section. The movable tube section having a fixed diaphragm plate that is detachable.

Abstract: Provided is a supporter in which it is possible to prevent floating of the supporter from the back portion of a wearer of the supporter in an upper side and a lower side of a back-contact section having a wide width and reliably support the waist portion of the wearer. The supporter 100 comprises: a band-shaped body section 10 provided with a back-contact section 11 which is brought into contact with the back portion of a wearer, and protruding sections 12 protruding to the right and left from both sides of the back-contact section 11; a pair of right and left auxiliary band sections 31 and 32 fixed so as to intersect one another in the vicinity of an upper side 11a of the back-contact section 11; a pair of right and left adjustment band sections 51 and 52 loosely inserted into annular rings 41 and 42 respectively disposed at the auxiliary band sections 31 and 32; and a band-shaped support band section 70 fixed to the vicinity of a lower side 11b of the back-contact section 11.

Abstract: An object of the present invention is to develop and provide a fiber-reinforced composite material having an “elongation” feature in addition to a high strength and a high elastic modulus. Further, an object of the present invention is to address problems of brittleness and peeling in the conventional fiber-reinforced composite materials. A fiber-reinforced composite material containing the bagworm silk thread as reinforcing fibers is provided.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Abstract: A toric intraocular lens includes a lens body, support portions, and connecting portions for connecting the lens body and the support portions. The lens is housed in an insertion apparatus that includes a tubular apparatus body having an insertion tube for the lens and a plunger for moving the lens. Each of the connecting portions is arranged at a position where the connecting portions face each other across a center of an optical axis of the lens body. One end of the flat meridian of the lens body is located at a position opposite to a position, with respect to an axis that passes through the center and connects the connecting portions, at which the plunger contacts the lens body. An angle between the flat meridian and an axis along which the lens is pushed by the plunger is larger than 0° and equal to or smaller than 90°.

Abstract: A wrist joint bandage includes a main body part including a woven fabric and having a band shape and a loop face, an anchor part joined to one end of the main body part, and an engaging part joined to the other end of the main body part and having a hook face such that the hook face detachably sticks to the loop face. The main body part has a winding part on one end side of the main body part and a supporting part on the other end side such that the winding part has a straight line shape and winds around a wrist of the wearer and that the supporting part has a straight line shape and extends from the back of the hand or the palm to the wrist. The supporting part and the winding part have the straight line shapes having the same width.

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an ?2 agonist for preventing or treating glaucoma.

Abstract: An intraocular lens insertion apparatus includes an apparatus body configured to include a housing member for housing an intraocular lens and an insertion tube member for ejecting the intraocular lens into an eyeball of a patient, a plunger configured to move in the apparatus body, and a hook member formed on the apparatus body for a user of the intraocular lens insertion apparatus to hook a finger when the user moves the plunger. The plunger is moved to a side of the insertion tube member, the intraocular lens housed in the housing member is pushed by a distal end of the plunger, and the intraocular lens is ejected from the insertion tube member, and a connecting member configured to connect an operability enhancing member for enhancing an operability of the plunger when the plunger is moved with the apparatus body is provided for the apparatus body.

Abstract: A knee joint supporter includes a first anchor having a loop face, a main body including second anchor, first supporting and second supporting, connections joining the anchors and connecting the first anchor and main body, a first engaging joined to the second supporting and having a hook face to stick to the loop face, a second engaging joined to the first anchor and having a hook face to stick to the loop face, and a third engaging joined to the first supporting and having a hook face to the loop face. The first anchor fastens around a thigh of a wear. The second anchor extends below popliteal region. The first supporting extends on one side from below part corresponding to a patella, and the second supporting extends on the other side of the part corresponding to the patella and crosses the first supporting below the part corresponding to the patella.

Abstract: An ankle joint bandage includes a main body part of woven fabric in band shape, an anchor part of woven fabric joined to one end of the main body part and having a loop face of a touch fastener, and an engaging part joined to the other end of the main body part and having a hook face of a touch fastener. The main body part has a winding part which winds around an ankle of a wearer, a first supporting part which extends from an instep to the ankle, and a second supporting part which extends from the ankle to the instep of the wearer to cross the first supporting part at an upper portion of the instep of the wearer, the anchor part fastens around part corresponding to a metatarsal bone of the wearer, and the engaging part detachably sticks to the loop face of the anchor part.

Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.

Abstract: A perimeter 2 capable of acquiring, as a threshold SV, a value corresponding to a response result of a subject 22 to an optotype presented with various brightness, for measurement points set across an entire measurement field of view of the ocular fundus, displaying the threshold SV as a threshold inspection result SHR and storing the same in a memory 13, comprises: a portion 15 for obtaining a pattern deviation PDV of the threshold SV relating to each measurement point RG, from the threshold inspection result SHR; a portion for 15 for obtaining a P value representing the obtained pattern deviation PDV for each measurement point RG as a probability variable, and generating a probability map image MAP4 indicating the measurement points RG separately for each P value; a portion 16 for selecting, from an abnormal measurement point group RG of points in the probability map image MAP4 in which at least a prescribed number of measurement points having a P value at most equal to 5% are continuous, and, of those, for

Abstract: [Problem] To enable imaging to be performed with appropriate timing. [Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition contains pemafibrate, a salt thereof or a solvate thereof in an amount of 0.017 to 4.2 mass % in terms of a free form of pemafibrate with respect to the total mass of the pharmaceutical composition.